- Abstract
- Core Tip
- Article Highlights
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (1801)
- Timeline of Article Publication (1)
- Authors Evaluation (2)
- Article Quality Tracking (0)
- Reader Comments (1)
- Reference Citation Analysis (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4973)
All Articles published online
|
Publishing Process of This Article
|
Feb 28, 2024 (publication date) through Aug 25, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wu HX, Ding XY, Xu YW, Yu MH, Li XM, Deng N, Chen JL. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2024; 30(8): 843-854 [PMID: 38516240 DOI: 10.3748/wjg.v30.i8.843] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i8/843.htm |
| Number | Citing Articles |
| 1 |
Yongfa Lei, Xiaotian Liang, Hua Zhu, Jin Wang, Xiaochen Zhang, Siliang Duan, Weiming Liang. Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1586914
|
| 2 |
Daniele Ferraro, Federica Falaschi, Luca Nazzaro, Giovanni Vennarecci. Impact of neoadjuvant multimodal therapy in the setting of locally advanced hepatocellular carcinoma. World Journal of Gastroenterology 2024; 30(28): 3452-3455 doi: 10.3748/wjg.v30.i28.3452
|
| 3 |
Yuhang Chen, Suoyi Dai, Chien-shan Cheng, Lianyu Chen. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Journal of Hematology & Oncology 2024; 17(1) doi: 10.1186/s13045-024-01647-1
|
| 4 |
Changjie Du, Hongyu Wu, Tao Zhong, Qilong Zhai, Jiajun Yuan, Jialun Peng, Rong Ma, Jinzheng Li. Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. Discover Oncology 2024; 15(1) doi: 10.1007/s12672-024-01026-9
|
| 5 |
Yue Chen, Luyao Jia, Yu Li, Wenhao Cui, Jukun Wang, Chao Zhang, Chunjing Bian, Tao Luo. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1466113
|
| 6 |
Wei Zhang, Zirong Liu, Hongjin Liu, Zhangkan Huang, Xiaozhun Huang, Lin Xu, Xu Che, Zhengyin Zhan. The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysis. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1573505
|
| 7 |
Deyu Lu, Lingling Zhou, Ziyi Zuo, Zhao Zhang, Xiangwu Zheng, Jialu Weng, Zhijie Yu, Jiansong Ji, Jinglin Xia. MRI Radiomics to Predict Early Treatment Response to TACE Combined with Lenvatinib Plus a PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Journal of Hepatocellular Carcinoma 2025; : 985 doi: 10.2147/JHC.S513696
|